Skip to main content

Autoinflammatory

Multinational recs. on Rx of JIA assoc. Uveitis: - Topical steroids are 1st line Rx - Systemic Rx if above fails or w/ poor prognosis or persistence - Options MTX, MMF then Humira EOW, then weekly ADA - Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd
Dr. John Cush @RheumNow( View Tweet )
Jun 25, 2022
31 systemic JIA pts: w/ systemic sxs (n=8), chronic arthritis (7), remission on meds (10) & remission off meds (6). High IL-18 levels & impaired IL-18 signaling in NK cells correlated with systemic Dz activity. High IL-18 impairs NK phosphorylation https://t.co/hKTRdhuQVN https://t.co/qM5jYB3yi5
Dr. John Cush @RheumNow( View Tweet )
Jun 20, 2022
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Dr. John Cush @RheumNow( View Tweet )
Jun 18, 2022
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.




  1. Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article
ice cubes

Topical therapies take centre stage

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 04, 2022
#EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
Jun 04, 2022
JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 04, 2022
Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 03, 2022
So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Jun 03, 2022
JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. ⁦@eular_org⁩ #EULAR2022 POS0014 ⁦@RheumNow⁩ https://t.co/j9IRgT9XJf
Jun 03, 2022
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
#EULAR2022 – Day 2 Report A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Dr. John Cush @RheumNow( View Tweet )
Jun 03, 2022
The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combination of clinical assessment, genetic testing and imaging to define the phenotype of SAID #EULAR2022 @RheumNow https://t.co/TGYmfExHxD
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 02, 2022
#Behcets. If topical oracort / steroids don’t work for Mucosal ulcers consider topical #tacrolimus https://t.co/7ZiLfdwZoP
Jun 02, 2022
Behcet disease: RCT Topical Tacrolimus for mouth ulcers in 40+pts ↘️VAS 2 wks & 3mo ↘️ Number of ulcers ↘️ Ulcer size and duration ↘️ Ulcer severity score #OP0046 #EULAR2022 @RheumNow
Jun 01, 2022
Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP

Richard Conway @RichardPAConway( View Tweet )

Jun 01, 2022
TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response in 20-25%. Maybe response criteria too strict, or maybe TCZ only effective for subgroup of patients @RheumNow #EULAR2022 OP0043 https://t.co/kNs8DMzXFB https://t.co/QMDk1IUkjx
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011, Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush @RheumNow( View Tweet )
May 27, 2022
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...https://t.co/u86Vd8bFGr#MedEdTwitter https://t.co/IpKqPoWM9R
Dr. John Cush @RheumNow( View Tweet )
May 26, 2022
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush @RheumNow( View Tweet )
May 25, 2022
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

May 20, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3
Dr. John Cush @RheumNow( View Tweet )
May 20, 2022
Differential diagnosis of dysphagia - when due to autoimmune dz is called Autoimmune neurogenic dysphagia - causes include inflammatory myopathies,inclusion body myositis, myasthenia gravis, Guillain–Barre, MS, NMO, paraneoplastic neuropathies https://t.co/oA0cPVJ5pJ https://t.co/58MyQwmxhL
Dr. John Cush @RheumNow( View Tweet )
May 17, 2022
×